Tempest Therapeutics, Inc.
TPST
$1.92
-$0.02-1.03%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 13.97M | 13.61M | 13.57M | 13.22M | 13.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.58M | 36.42M | 43.37M | 44.99M | 42.03M |
| Operating Income | -26.58M | -36.42M | -43.37M | -44.99M | -42.03M |
| Income Before Tax | -26.26M | -36.05M | -43.10M | -44.80M | -41.84M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -26.26 | -36.05 | -43.10 | -44.80 | -41.84 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -26.26M | -36.05M | -43.10M | -44.80M | -41.84M |
| EBIT | -26.58M | -36.42M | -43.37M | -44.99M | -42.03M |
| EBITDA | -26.31M | -36.17M | -43.09M | -44.62M | -41.64M |
| EPS Basic | -6.84 | -10.40 | -14.93 | -18.37 | -19.84 |
| Normalized Basic EPS | -4.27 | -6.50 | -9.33 | -11.48 | -12.40 |
| EPS Diluted | -6.84 | -10.40 | -14.93 | -18.37 | -19.84 |
| Normalized Diluted EPS | -4.27 | -6.50 | -9.33 | -11.48 | -12.40 |
| Average Basic Shares Outstanding | 16.59M | 14.83M | 12.38M | 10.31M | 8.58M |
| Average Diluted Shares Outstanding | 16.59M | 14.83M | 12.38M | 10.31M | 8.58M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |